Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

EVA1A regulates fatty acid transporter CD36 in fatty liver disease

9

Mar 2026

EVA1A regulates fatty acid transporter CD36 in fatty liver disease

Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, obesity, and diabetes prevalence, making it one of the most common chronic liver diseases worldwide.

Specific gut bacteria may signal long-term risk of heart and metabolic disease

9

Mar 2026

Specific gut bacteria may signal long-term risk of heart and metabolic disease

Researchers analyzed gut microbiome profiles from 4,792 adults in the HELIUS cohort and tracked cardiometabolic outcomes over time to determine whether specific microbes predict disease risk. Certain microbes were linked to higher or lower cardiovascular risk, while plant-derived microbial metabolites suggested potential diet–microbiome interactions influencing heart health.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.